UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy

Tsai, RM; Lobach, I; Bang, J; Whitwell, JL; Senjem, ML; Jack, CR; Rosen, H; ... AL-108-231 Investigators; + view all (2016) Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. Parkinsonism & Related Disorders , 28 pp. 29-35. 10.1016/j.parkreldis.2016.04.006. Green open access

[thumbnail of nihms-785506.pdf]
Preview
Text
nihms-785506.pdf - Accepted Version

Download (284kB) | Preview

Abstract

INTRODUCTION: There are no effective treatments for progressive supranuclear palsy (PSP). Volumetric MRI (vMRI) may be a useful surrogate outcome measure in PSP clinical trials. The goal of the study was to evaluate the potential of vMRI to correlate with clinical outcomes from an international clinical trial population. METHODS: PSP patients (n = 198) from the AL-108-231 trial who had high quality vMRI and Progressive Supranuclear Palsy Rating Scale (PSPRS), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Schwab and England Activities of Daily Living (SEADL), Color Trails Test, Geriatric Depression Screen (GDS) and one year Clinician Global Impression of Change (CGIC) data from the baseline and 52 week visits were included. Linear regression was used to relate baseline values and annual clinical rating scale changes to annual regional vMRI changes (whole brain, ventricular, midbrain and superior cerebellar peduncle volumes). RESULTS: Effect sizes (Cohen's d) measuring disease progression over one year were largest for vMRI (midbrain [1.27] and ventricular volume [1.31]) but similar to PSPRS (1.26). After multiple comparison adjustment, annual changes in PSPRS, RBANS, SEADL, Color Trails Test, GDS and one year CGIC were modestly correlated with annual vMRI changes (p < 0.05). Baseline neuropsychological status on RBANS (p = 0.019) and Color Trails (p < 0.01) predicted annual midbrain atrophy rates. CONCLUSION: Standard vMRI measurements are sensitive to disease progression in large, multicenter PSP clinical trials, but are not well correlated with clinical changes. vMRI changes may be useful as supportive endpoints in PSP trials.

Type: Article
Title: Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.parkreldis.2016.04.006
Publisher version: https://doi.org/10.1016/j.parkreldis.2016.04.006
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions
Keywords: Biomarkers, Clinical trials, Imaging, MRI, Progressive supranuclear palsy, Atrophy, Biomarkers, Brain, Disease Progression, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Supranuclear Palsy, Progressive
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Movement Neurosciences
URI: https://discovery.ucl.ac.uk/id/eprint/10055847
Downloads since deposit
88Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item